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Background. Maintaining gastrointestinal (GI) microbiome diversity plays a key role during allogeneic stem cell transplantation 
(ASCT), and loss of diversity correlates with acute GI graft versus host disease (GvHD) and poor outcomes.
Methods. In this retrospective analysis of 161 ASCT patients, we used serial analyses of urinary 3-indoxyl sulfate (3-IS) levels 
and GI microbiome parameters within the first 10 days after ASCT to identify potential commensal microbiota–sparing antibiotics. 
Based on antibiotic activity, we formed 3 subgroups (Rifaximin without systemic antibiotics, Rifaximin with systemic antibiotics, 
and Ciprofloxacin/Metronidazole with/without systemic antibiotics).
Results. Mono-antibiosis with Rifaximin revealed higher 3-IS levels (P  <  .001), higher Clostridium cluster XIVa (CCXIVa) 
abundance (P  =  .004), and higher Shannon indices (P  =  .01) compared to Ciprofloxacin/Metronidazole with/without systemic 
antibiotics. Rifaximin followed by systemic antibiotics maintained microbiome diversity compared to Ciprofloxacin/Metronidazole 
with/without systemic antibiotics, as these patients showed still higher 3-IS levels (P = .04), higher CCXIVa copy numbers (P = .01), 
and higher Shannon indexes (P = .01). Even for this larger cohort of patients, the outcome was superior with regard to GI GvHD 
(P = .05) and lower transplant-related mortality (P < .001) for patients receiving Rifaximin plus systemic antibiotics compared to 
other types of systemic antibiotic treatment. Antibiosis with Ciprofloxacin/Metronidazole (n = 12, P = .01), Piperacillin/Tazobactam 
(n = 52, P = .01), Meropenem/Vancomycin (n = 16, P = .003), Ceftazidime (n = 10, P = .03), or multiple systemic antibiotics (n = 53, 
P = .001) showed significantly lower 3-IS levels compared to mono-antibiosis with Rifaximin (n = 14) or intravenous Vancomycin 
(n = 4, not statistically significant).
Conclusions. Different types of antibiotic treatments show different impacts on markers of microbiome diversity. The identi-
fication of antibiotics sparing commensal bacteria remains an ongoing challenge. However, Rifaximin allowed a higher intestinal 
microbiome diversity, even in the presence of systemic broad-spectrum antibiotics.
Keywords. broad-spectrum antibiotics; gut microbiome; allogeneic stem cell transplantation; acute intestinal graft versus host 
disease.
 The human gastrointestinal (GI) tract harbors a complex and 
diverse community of commensal microbiota, providing a vari-
ety of beneficial effects to the host. They contribute to the main-
tenance of intestinal homeostasis and epithelial integrity and 
exert anti-inflammatory effects by interacting with the mucosal 
immune system [1, 2]. Therefore, it is hardly surprising that 
intestinal dysbiosis is associated with inflammatory processes 
[3] contributing to the pathophysiology of different diseases, 
ranging from inflammatory bowel disease [4] via gastrointesti-
nal carcinogenesis [5, 6] to metabolic syndromes [7] to neuro-
logical disorders [8].
A major risk factor causing disruptions of the intestinal 
microbiome is the use of broad-spectrum antibiotics. Patients 
undergoing allogeneic stem cell transplantation (ASCT) are 
at high risk for intestinal microbiota disruptions [9]. To pre-
vent neutropenic infections, they usually receive prophylactic 
antibiotics, but still the majority of patients develop fevers and 
require additional therapeutic antibiotics [10, 11]. Furthermore, 
conditioning-related epithelial damage, changes of alimen-
tary habits, and parenteral nutrition enhance intestinal dysbi-
osis during transplantation [12]. Alterations of the intestinal 
microbiota diversity seem to be linked with the outcome after 
ASCT, as low intestinal microbiota diversity was found to be 
associated with increased graft versus host disease (GvHD)-
related mortality and worse overall survival (OS) [12, 13]. Even 
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correlations between the timing of antibiotic treatment, the kind of 
antibiotics used for the prophylaxis and treatment of neutrope-
nic infections, and outcomes could be observed, resulting in the 
need to reevaluate the benefits of current antibiotic standards 
in ASCT [9, 14]. As a first step, we addressed the question of 
whether specific antibiotics have differential impacts on micro-
biota diversity and, thus, can lead providers to the selection of 
antibiotics with microbiota-sparing effects.
PATIENTS AND METHODS
Patients
A total of 161 adult patients undergoing ASCT at the 
University Hospital Regensburg were included in our retro-
spective analysis. Inclusion criteria were hemato-oncologic 
disease requiring ASCT, an age above 18  years, and receiv-
ing non-T cell depleted grafts. The Ethics Committee of the 
University Hospital Regensburg approved the study (02/220) 
and, after written informed consent, the patients’ stool and 
urinary specimens were collected on a weekly basis from 
admission until day 10 after ASCT: prior to admission, spec-
imens were collected at least once between days -2 to +2 and 
+2 to +10. All specimens were stored at -80°C until analysis. 
Urinary samples were available in 161 patients and additional 
stool samples were available in a subgroup of 62 patients. Pre-
transplant urinary and stool samples were not available for 2 
patients.
In our cohort, 55 patients received Ciprofloxacin at 500 mg 
2 times a day and Metronidazole at 400  mg 3 times a day 
for antibiotic prophylaxis, typically starting 8  days prior to 
ASCT and going until 28 days post-transplant. In April 2012, 
we switched our standard gut decontamination regimen to 
Rifaximin at 200mg twice a day (n = 106), due to an increasing 
number of patients with Vancomycin-resistant enterococci. 
Rifaximin is a Rifamycin-derivative with broad-spectrum 
activity and negligible intestinal resorption [15]. In cases of 
neutropenic infections, Piperacillin/Tazobactam was stan-
dardly used according to the guidelines of the European 
Leukemia network for empiric first-line therapy and was fol-
lowed by Meropenem/Vancomycin as a second-line therapy 
[16]. Patients with known colonization with gram-negative 
bacteria, penicillin-resistant bacteria, or clinical signs of sep-
sis were initially treated with Meropenem/Vancomycin. In 
case of a known intolerance against penicillin or carbapenem, 
Ceftazidime was used as an antibiotic first- or second-line 
therapy instead. Patients with local signs of an infection of 
the central venous catheter were treated with intravenous 
Vancomycin. The clinical standard of therapeutic adminis-
tration of systemic antibiotics did not differ between the 2 
decontamination groups. For each patient, the time point of 
the beginning and the duration of systemic antibiotic ther-
apy were exactly documented. In this retrospective analysis, 
we focused on patients who received monotherapy with dif-
ferent kinds of antibiotics within the first 10 days after ASCT 
and classified patients, according to their antibiotic exposure, 
into the following groups: patients with gut decontamina-
tion only (Rifaximin vs. Ciprofloxacin/Metronidazole) and 
patients with gut decontamination and a single kind of sys-
temic broad-spectrum antibiotic (Piperacillin/Tazobactam vs. 
Meropenem/Vancomycin vs. Ceftazidime vs. Vancomycin). In 
case of administration of several broad-spectrum antibiotics 
within the first 10 days, patients were classified into the group 
with multiple systemic antibiotics.
The interval until day 10 was chosen because many patients 
with antibiotic monotherapy switch to second-line antibiosis 
in this timeframe, therefore not allowing for the differentiation 
of effects at later times post-transplant. Additionally, we have 
previously shown that the first 10 days after ASCT are the most 
critical with regard to microbiota effects on patients’ outcomes 
post-transplant [17]. Patients were attributed to the different 
antibiotic groups according to the antibiotic with the broad-
est spectrum of efficacy that was given more than 2 days. We 
subsequently divided patients into 3 different subgroups: (1) 
Rifaximin treatment without further broad-spectrum antibi-
otics (n = 14), (2) Rifaximin followed by additional systemic 
broad-spectrum antibiotics (n  =  92), and (3) Ciprofloxacin/
Metronidazole administration with/without systemic 
broad-spectrum antibiotics (n  =  55). None of the patients 
(0/14) in the Rifaximin without systemic antibiotics group, 
8.7% (8/92) of patients in the Rifaximin group followed by 
systemic antibiotic treatment, and 25.5% (14/55) of patients in 
the Ciprofloxacin/Metronidazole group with/without systemic 
broad-spectrum antibiotics received the standard systemic 
conditioning regimen. A  separate analysis of Ciprofloxacin/
Metronidazole alone and Ciprofloxacin/Metronidazole fol-
lowed by systemic antibiotics revealed a comparable time 
course of 3-indoxyl sulfate (3-IS) levels. As the number of 
patients receiving Ciprofloxacin/Metronidazole alone was very 
small with regard to microbiota analyses, we therefore com-
bined both groups.
Within the first 10  days after ASCT, 74.5% (n  =  41) of 
patients with Ciprofloxacin/Metronidazole and 86.8% (n = 92) 
of patients with Rifaximin required additional systemic 
broad-spectrum antibiotic treatment. Altogether, 89.1% (49/55) 
of Ciprofloxacin/Metronidazole patients and 93.4% (99/106) 
of Rifaximin patients received systemic antibiotics during the 
course of ASCT (data are not statistically significant [ns]). 
Patients’ characteristics are shown in Table 1.
Analysis of Urinary 3-Indoxyl Sulfate Levels
In 161 patients, urinary 3-IS levels were analyzed by reversed-
phase liquid chromatography–electrospray ionization tandem 
mass spectrometry, as previously described, and corrected in 
relation to the creatine value [17].
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Quantification of Clostridium Cluster XIVa 16S-Ribosomal 
Ribonucleic Acid Gene Copies by Quantitative Polymerase 
Chain Reaction
Using Clostridium cluster XIVa (CCXIVa) group-specific prim-
ers [18] and SYBR® Green I Master (Roche) quantitative poly-
merase chain reaction reagents, 16S-rRNA gene copy numbers 
of CCXIVa species were determined in fecal deoxyribonucleic 
acid preparations (n = 62) by real-time quantitative polymerase 
chain reaction on a LightCycler 480 II instrument (Roche). 
Full-length 16S-rRNA gene amplicons of Eubacterium rectale 
DSM 17629, cloned into the pGEM® T-Easy vector (Invitrogen), 
served as quantification standards.
Analysis of Enterococcus spp. 16S-rRNA Gene Copies by 
Quantitative Polymerase Chain Reaction
Enterococcus species were quantified analogous to CCIVa in 
the same subgroup (n = 62), except that genus-specific prim-
ers [19] and Enterococcus faecalis ATCC 29212 quantification 
standards were used.
Analysis of Intestinal Microbiome Diversity
In the same 62 patients, 16S-rRNA gene analyses of stool speci-
mens were performed. Extraction of nucleic acids and sequenc-
ing of variable V3-V6 16S-rRNA gene regions were performed 
using a GS FLX+ system, as described before [20]. Reads were 
demultiplexed and quality filtered with the QIIME 1.9.1 soft-
ware package, using default parameters [21]. Operational tax-
onomic units were clustered at 99% pairwise identity using 
the vsearch 2.4.3 package [22]. Taxonomy was assigned to 
OTUs using UCLUST v1.2.22q [23] and the SILVA release 128 
reference database [24]. The α-diversity was determined at dif-
ferent time points between admission and day 28 after ASCT by 
calculating the Shannon diversity index [25].
Clinical Outcome
For assessment of clinical outcomes in relation to antibiotic 
regimen, the incidences of severe GI GvHD (stage II-IV), 
transplant-related mortality (TRM), and OS were evaluated. 
In addition, data regarding fevers of unknown origin and bac-
teremia were analyzed, as well as intestinal infections with 
Clostridium difficile.
Bioinformatics and Data Analysis
Continuous data are presented descriptively as mean ± stan-
dard deviation and range. Group comparisons were performed 
by 2-sided Mann-Whitney U-tests due to non-normal data 
distributions. Absolute and relative frequencies were given for 
categorical data and compared between study groups by chi-
squared tests. All hypotheses were tested in an exploratory man-
ner on a 2-sided 5% significance level. Statistical analyses were 
performed using IBM SPSS Statistics 22 (SPSS Inc, Chicago, IL).
RESULTS
Direct Effects of Antibiotic Groups on Commensal Bacteria and Diversity
Based on the systemic activity of Ciprofloxacin/
Metronidazole, we classified our cohort in relation to anti-
biotic treatment into 3 different subgroups, as mentioned 
above. Again, 3-IS concentrations between day -2 and day 10 
were higher in the Rifaximin group without systemic anti-
biotics (23.4  ±  14.7, 7.2–59.4  µmol/mmol creatinine [crea]) 
compared to Ciprofloxacin/Metronidazole with/without sys-
temic antibiotics (7.5 ± 9.0, 0–40.2 µmol/mmol crea, P < .001) 
and Rifaximin followed by systemic antibiotics (13.2 ± 16.3, 
0–101.9  µmol/mmol crea, P  =  .005). More specifically, we 
found a higher abundance of CCXIVa in the Rifaximin group 
without systemic antibiotics compared to the Ciprofloxacin/
Metronidazole with/without systemic antibiotics (P =  .004), 
whereas there was only a trend compared to the Rifaximin 
group followed by systemic antibiotic treatment (P  =  .06; 
Figure 1). Similarly, the Shannon index again was higher in 
the Rifaximin group without systemic antibiotics than in the 
Ciprofloxacin/Metronidazole group with/without systemic 
broad-spectrum antibiotics (P =  .01), whereas no difference 
was found between the Rifaximin groups with and without 
systemic antibiotics (ns; Figure 2). Enterococcal load in the 
Rifaximin group without systemic antibiotics was lower but, 
due to the high variability, was not statistically significant 
compared to the other 2 antibiotic groups (ns; Figure 3). No 
differences in any microbiome markers were found in the 
pre-transplant situation between the 3 different antibiotic 
groups (ns). Detailed information of the subgroups is pro-
vided in Supplementary Table 1.
Table 1. Summary of Patient Characteristics
Age, years 51.0 ± 11.7
Antibiotic treatment
 Ciprofloxacin/Metronidazole 7.4% (n = 12)
 Piperacillin/Tazobactam 32.3% (n = 52)
 Meropenem/Vancomycin 9.9% (n = 16)
 Ceftazidime 6.2% (n = 10)
 Multiple systemic antibiotics 32.9% (n = 53)
 Vancomycin 2.5% (n = 4)
 Rifaximin 8.7% (n = 14)
Diagnosis
 Acute leukemia 54.7% (n = 87)
 Lymphatic neoplasia 21.7% (n = 35)
 Myelodysplastic syndrome 13.0% (n = 21)
 Myeloproliferative syndrome 8.7% (n = 14)
 Aplastic anemia 2.5% (n = 4)
Stage of underlying disease
 Early/intermediate 64.6% (n = 104)
 Advanced 35.4% (n = 57)
Donor
 Sibling 29.8% (n = 48)
 Unrelated donor 70.2% (n = 113)
Conditioning
 Reduced intensity 86.3% (n = 139)
 Standard 13.7% (n = 22)
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Rifaximin Prophylaxis Followed by Systemic Antibiotics Preserves 
Microbiome Diversity Compared to Prophylaxis With Ciprofloxacin/
Metronidazole and Correlates With Superior Outcome
Comparing the Rifaximin group followed by systemic 
broad-spectrum antibiotics with all other types of systemic 
antibiotics without Rifaximin, Rifaximin seemed to maintain 
a microbiome protective effect despite the use of additional 
broad-spectrum antibiotics. This resulted in higher 3-IS con-
centrations (13.2 ± 16.3, 0–101.9 µmol/mmol crea to 7.5 ± 9.0, 
0–40.2  µmol/mmol crea; P  =  .04), higher CCXIVa levels 
(2.0 × 109 ± 3.2 × 109, 0–1.3 × 1010 to 1.9 × 108 ± 5.0 × 108, 
0–1.4 × 109; P = .01), and higher Shannon indexes (2.2 ± 0.9, 
0.2–3.8 to 1.2  ±  1.0, 0.1–3.4, P  =  .01) for Rifaximin fol-
lowed by broad-spectrum antibiotics. The enterococcal load 
was lower in the Rifaximin followed by systemic antibiot-
ics group (2.8 ×  109  ±  5.2 ×  109, 0–3.2 ×  1010) compared to 
all other types of antibiotic treatment without Rifaximin 
(7.7 × 109 ± 9.6 × 109, 4.4 × 105–2.8 × 1010), but the difference 
did not reach statistical significance (ns). The protective effect 
of Rifaximin was still observed when a direct comparison of 
Rifaximin combined with 1 broad-spectrum antibiotic with 
Ciprofloxacin/Metronodiazole alone was performed (data not 
shown). The overall duration of additional systemic antibiotic 
treatments did not differ between the Rifaximin plus systemic 
antibiotic group (19.8  ±  9.1, 2–40 d) and the Ciprofloxacin/
Metronodiazole with/without systemic antibiotic group 
(16.3 ± 10.4, 0–40 d; ns)
Similarly, Rifaximin followed by additional systemic antibiot-
ics was associated with differences in clinical outcome variables, 
such as GI GvHD, TRM, and OS, compared to all other types 
of systemic antibiotic treatment. This resulted in a lower rate of 
severe GI GvHD (P = .05), lower TRM (P < .001), and higher 
OS (P =  .001) in the Rifaximin plus systemic antibiotic group 
compared to other types of systemic antibiotic treatments. No 
differences between the 2 groups were observed for fevers of 
unknown origin or bacteremia (ns; Table 2). A GI infection with 
Clostridium difficile was observed in only 1 patient of the study 
Figure  2. Shannon diversity index in the 3 different antibiotic groups. The 
post-transplant Shannon index was higher in the Rifaximin group without systemic 
antibiotics than in the Ciprofloxacin/Metronidazole group with/without systemic 
broad-spectrum antibiotics (P = .01). No difference was found between the Rifaximin 
groups with and without systemic antibiotics. No differences in Shannon diversity 
index were observed in the pre-transplant situation (Mann-Whitney U-test).
Figure 3. Enterococcus species 16S-RNA gene copy numbers in relation to anti-
biotic treatment within the first 10 days post-transplant compared to the pre-trans-
plant situation. The enterococcal load in the Rifaximin group without systemic 
antibiotics was lower but, due to the high variability, not statistically significant 
compared to the other 2 antibiotic groups. No differences in enterococcal load were 
observed in the pre-transplant situation (Mann-Whitney U-test).
Figure 1. Clostridium cluster XIVa (CCXIVa) copy numbers in relation to antibiotic 
treatment within the first 10 days post-transplant, compared to the pre-transplant 
situation. CCXIVa copy numbers were significantly higher in the Rifaximin group 
without systemic antibiotics, compared to the Ciprofloxacin/Metronidazole with/
without systemic antibiotics (P  =  .004), whereas there was only a trend with-
out significance when compared to the Rifaximin group with systemic antibiotic 
treatment (P = .06). No differences in CCXIVa copy numbers were observed in the 
pre-transplant situation (P = ns, Mann-Whitney U-test).
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cohort. This patient received Rifaximin for prophylaxis but also 
received multiple additional systemic antibiotic treatments.
Impact of Individual Antibiotic Treatment Strategies on Intestinal 
Microbiome Diversity
Analyzing the type of antibiotic treatment within the first 
10 days after ASCT, we observed significantly lower 3-IS lev-
els for different antibiotic groups, including Ciprofloxacin/
Metronidazole, Piperacillin/Tazobactam, Meropenem/
Vancomycin, and Ceftazidime or multiple systemic antibiot-
ics (P ≤ .03), except for in those patients receiving intravenous 
Vancomycin alone (ns) or mono-antibiosis with Rifaximin. In 
contrast, no statistically significant differences in 3-IS levels 
were measured between any antibiotic groups in the pre-trans-
plant situation (ns; Figure 4). The extent of suppression of 3-IS 
levels between day -2 and 10 showed no major differences 
between the individual groups of antibiotics (Ciprofloxacin/
Metronidazole, Piperacillin/Tazobactam, Meropenem/ 
Vancomycin, and Ceftazidime or multiple systemic antibi-
otics), suggesting a similar suppression of commensal bacte-
ria even for the group receiving Ciprofloxacin/Metronidazole 
alone. This is also reflected in a comparison of microbiota 
profiles before transplantation with bacterial distributions 
from patients receiving Rifaximin only or patients receiving 
Ciprofloxacin/Metronidazole and/or other broad- spectrum 
antibiotics (Figure 5). The latter group is distinguished by an 
overall reduction of bacterial richness, which is related to the 
relative predominance of various bacterial genera, such as 
Bacteroides, Enterococcus, Faecalibacterium, or Peptoniphilus.
DISCUSSION
Intestinal microbiota diversity plays a key role in the pathophys-
iology of acute GI GvHD and, therefore, significantly influences 
TRM of patients after ASCT [12, 13]. Commensal bacteria like 
Clostridium cluster XIVa species seem to have beneficial effects 
Table 2. Outcome of patients after allogeneic stem cell transplantation is associated with type of prophylactic antibiotics. 
N = 147 Neutropenic fever Bacteremia GI GvHD (II-IV) TRM OS
Rifaximin followed by systemic antibiotics (32/92)
34.8%
(24/92)
26.1%
(13/92)
14.1%
(12/92)
13.0%
(64/92)
69.6%
Ciprofloxacin/Metronidazole +/- systemic antibiotics (19/55)
34.5%
(15/55)
27.3%
(15/55)
27.3%
(23/55)
41.8%
(23/55)
41.8%
P-value .89 .96 .05 <.001 .001
Rifaximin, followed by additional systemic antibiotic treatment, correlated with a lower rate of severe GI GvHD (P = .05), lower TRM (P < .001) and higher OS (P = .001) compared to other 
types of systemic antibiotic treatment (chi-squared test), whereas no difference was observed for fevers of unknown origin and bacteremia.
Abbreviations: GI, gastrointestinal; GvHD, graft versus host disease; II-IV, severe stages of GvHD; OS, overall survival; TRM, transplant-related mortality.
Figure 4. Course of 3-indoxyl sulfate (3-IS) levels in relation to the type of systemic antibiotic treatment. 3-IS levels were significantly lower for all antibiotic groups 
(P ≤ .03) within the first 10 days after allogeneic stem cell transplantation, except for the Vancomycin group compared to single administration of Rifaximin. No differences 
in 3-IS levels were observed in the pre-transplant situation (Mann-Whitney U-test).
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by maintaining intestinal homeostasis and epithelial integrity 
and by inducing regulatory T-cells [26]. In contrast, loss of these 
protective bacteria, as shown for the genus Blautia, has been 
associated with increased GvHD-related mortality [12]. Similar 
results were found by our group, as we identified low levels 
of urinary 3-IS, a tryptophan metabolite of colonic commen-
sal bacteria, early after ASCT as a predictor of poor outcomes 
post-transplant [17]. In the setting of ASCT, the composition of 
intestinal microbiota is influenced by several factors, like con-
ditioning-related epithelial damage, changes of alimentary hab-
its, and parenteral nutrition [12]. However, a major risk factor 
causing intestinal dysbiosis is the use of systemic antibiotics for 
the prophylaxis and therapy of neutropenic infections [27–29]. 
Even in the non-ASCT setting, it has been shown that antibi-
otic administration in general reduces gut microbiome diver-
sity: Iizumi et al. reviewed many reports indicating associations 
between classes, dosages, and periods of exposure of antibiotics, 
alterations of the gut microbiome composition, and the occur-
rence of autoimmune diseases like obesity and allergic asthma 
in children [30].
The increasing understanding of the interactions between 
antibiotics, bacterial dysbiosis, the pathogenesis of acute GI 
GvHD, and poor outcomes post-transplant has contributed 
to providers reconsidering antibiotic standards in the ASCT 
setting [31]. Since van Bekkum et  al. [32] and Beelen et  al. 
[33] demonstrated in mice and in clinical studies that intes-
tinal bacteria play an important role for the development and 
severity of GI GvHD, strategies of total or selective gut decon-
tamination became the clinical standards for years. However, 
the development of new, culture-independent techniques 
like metagenomic sequencing have allowed deeper insights 
into the complex and dynamic network of intestinal micro-
biota and have identified the bacteria and metabolites asso-
ciated with protective effects on gut homeostasis [34]. Shono 
and colleagues [9] analyzed the impact of different kinds of 
broad-spectrum antibiotics for the treatment of neutrope-
nic fever on GvHD-related mortality. The use of Imipenem/
Cilastatin and Piperacillin/Tazobactam was associated with 
severe perturbation of gut microbial compositions and an 
increased GvHD-related mortality rate. In contrast, the admin-
istration of Aztreonam or Cefepime, antibiotics with a limited 
spectrum of activity against anaerobes like Clostridiales, was 
not associated with GvHD-related mortality. This led to their 
hypothesis that selective antibiotics that offer protection to 
Figure 5. Barplots of bacterial genus distribution in relation to type of antibiotic treatment within the first 10 days post-transplant in representatively selected samples. 
Rifaximin preserved intestinal microbiota diversity, which was comparable to the pre-transplant situation. On the contrary, treatment with Ciprofloxacin/Metronidazole with/
without systemic antibiotics led to a loss of richness. Bacterial profiles were mainly dominated by the genera Akkermansia (81%: AAV3 and 51%: QX2), Eubacterium (98%: 
QP3), or Enterococcus (90%: LW2). Only genera above 1% abundance in at least 1 sample are depicted.
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commensal bacteria might have beneficial effects on the out-
comes of patients after ASCT [9].
In the current retrospective analysis, we aimed to evaluate 
the different types of antibiotics used for the prophylaxis and 
therapy of neutropenic infections regarding their impact on 
microbiome diversity and their protective effects on commen-
sal bacteria within the first 10 days after ASCT. The effects of 
Ciprofloxacin/Metronidazole, Piperacillin/Tazobactam, and 
Meropenem/Vancomycin on intestinal microbiota diversity 
and Clostridial abundance were comparable. In addition, treat-
ment with 1 of these antibiotics had a similar impact on intes-
tinal microbiota composition compared with the concurrent 
administration of several broad-spectrum antibiotics. Even 
monotherapy with Ceftazidime showed no beneficial effect on 
intestinal microbiome diversity, although Ceftazidime belongs 
to the same antibiotic group of cephalosporins as Cefepime, 
which was reported by Shono et al. to exert protective effects on 
microbiome composition [9].
However, compared to all other types of antibiotics, Rifaximin 
mono-antibiosis was able to preserve intestinal microbiome 
heterogeneity, as demonstrated by several intestinal microbi-
ome markers in this analysis. Rifaximin seemed to maintain a 
protective effect even in the presence of additional broad-spec-
trum antibiotics. The clinical relevance of these results was 
demonstrated by lower TRM and higher OS during Rifaximin 
prophylaxis. Fevers of unknown origin or infectious complica-
tions were not increased in the Rifaximin group compared to 
Ciprofloxacin/Metronidazole. This is in line with our previous 
study [11] showing that gut decontamination with Rifaximin 
resulted in lower positivity for Enterococcus faecalis and faecium 
than in patients with Ciprofloxacin/Metronidazole. Similarly, 
higher 3-IS concentrations were measured for patients treated 
with Rifaximin compared to Ciprofloxacin/Metronidazole. 
However, only 1 microbiome marker was available in this pre-
vious study [11]. Furthermore, 3-IS as a marker of microbiome 
diversity might not be as robust as traditional fecal parame-
ters. Therefore, in the current study, we expanded the analy-
sis towards a variety of different parameters, which indicate a 
higher microbiome diversity by the use of Rifaximin.
Rifaximin is a non-absorbable derivative of Rifamycin with 
so-called eubiotic effects [35]. Rifaximin is able to induce remis-
sion in patients with active Crohn’s disease and ulcerative colitis, 
most probably by a modulation of the intestinal microbiome. 
Whereas Rifaximin doesn’t affect the overall gut microbiota 
composition, it has been demonstrated to enhance the concen-
tration of beneficial bacteria like Bifidobacterium, Atopobium, 
and Faecalibacterium prausnitzii [35, 36]. Furthermore, 
Rifaximin alters bacterial virulence, reduces bacterial adher-
ence to gut mucosa and internalization, and downregulates 
intestinal inflammatory activity by inducing the pregnane X 
receptor – nuclear factor ‘kappa-light-chain-enhancer’ of acti-
vated B-cells pathway [35–37]. Whether 1 of these mechanisms 
contributed to the suggested reduction of microbiota damage 
in patients receiving Rifaximin and systemic antibiotics in our 
study is currently unclear and needs further investigation.
Consequently, not only new strategies of gut decontamina-
tion, but even no antibiotic prophylaxis is currently considered 
to be protective toward commensal bacteria. In 2017, Routy and 
colleagues first analyzed the impact of antibiotic gut decontam-
ination vs no antibiotic prophylaxis on the frequency of severe 
acute GI GvHD and mortality in 500 patients undergoing ASCT 
[38]. In the group of patients receiving antibiotics for prophy-
laxis, the rate of severe, grade II-IV acute GI GvHD was higher 
(odds ratio = 1.8) and OS was decreased (hazard ratio = 1.6) 
compared to patients without antibiotics [38].
These new insights into the impact of systemic antibiotics 
on the pathogenesis of acute GI GvHD and the outcomes of 
patients after ASCT provide a new aspect to the topic of anti-
biotic stewardship that is intended to improve the quality of 
antibiotic therapy for optimizing clinical treatment results 
and for reducing toxicity and bacterial resistance. A  further 
aspect might result in selecting the most appropriate antibi-
otics, considering the protection of commensal bacteria and 
their anti-inflammatory effects, as recommended by Shono 
et  al. [9]. Particularly in the ASCT setting, these associations 
bring us into conflict: broad-spectrum antibiotics are indis-
pensable to treat neutropenic infections and to save lives, 
but the use of broad-spectrum antibiotics correlates with the 
occurrence of severe GI GvHD and affects mortality rates in 
a detrimental way. Therefore, strategies are required to protect 
beneficial microbiota: for example, by the use of selective antibi-
otics with clostridial sparing effects, prebiotics, which stimulate 
the growth and function of specific gut microbiota, as well as 
postbiotics. Another possibility is the reconstitution of intes-
tinal microbiota by a fecal microbiota transfer after treatment 
with systemic antibiotics [39]. The first promising results were 
reported by Kakihana et al. using fecal microbiota transfers for 
the treatment of patients with steroid-resistant GI GvHD [40]. 
The protection of balanced microbiomes becomes more and 
more important, not only in the setting of ASCT, but also in 
anti-cancer therapy of other hemato-oncologic diseases, since 
it has been shown that anti-tumoral immune responses seem to 
rely on gut microbiota [41].
In summary, the identification of the complex interactions 
between the intestinal microbiome and acute GI GvHD is of 
great importance and is required for finding new possibili-
ties to modulate microbiome composition during the course 
of ASCT. The choice of antibiotics might be a step in this 
direction.
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